drugset
Drugs / Chimeric antigen receptor-modified T (CAR-T) cell therapy
last change Feb 2024 re-read 2 minutes ago

Chimeric antigen receptor-modified T (CAR-T) cell therapy

also known as CAR-T

Cell therapy targets CD19

Developed for
B-cell non-Hodgkin lymphoma
Investigated by
Affiliated Hospital of Jiangnan University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The Affiliated People's Hospital of Ningbo University · The First Affiliated Hospital of Soochow University · The General Hospital of Western Theater Command · West China Hospital
+2 more · Wuxi No. 2 People's Hospital · Yixing People's Hospital

Trials 1 · a red edge is where a trial was stopped

today NCT05322330 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05322330 Feb 2022 → Feb 2024 B-cell non-Hodgkin lymphoma The First Affiliated Hospital of Soochow University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Chimeric antigen receptor-modified T (CAR-T) cell therapy “Chimeric antigen receptor-modified T (CAR-T) cell therapy” NCT05322330 ↗
Known as CAR-T ClinicalTrials.gov intervention name — accepted as the source's own label NCT05322330 ↗
Modality Cell therapy “CAR-T therapy targeting CD19” NCT05322330 ↗
Route Intravenous “2-5×10\^6 CAR-T/kg，ivgtt。” NCT05322330 ↗
Target CD19 “CAR-T therapy targeting CD19” NCT05322330 ↗